Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07592871
Recruiting Observational

Cohort of Lower-Extremity Sports Injuries and Degeneration(Yongjiang Cohort)

NCT07592871 · tracked via the Priya Life Science China tracker
Sponsor
Ningbo No.2 Hospital
Phase
Observational
Started
2026-06-01
Last updated
2026-08-17

Condition(s) studied

Osteoarthritis (OA) of the Knee

Investigational drug(s) / intervention(s)

Routine Clinical Care

Routine Clinical Care: Participants will receive routine clinical care as determined by their treating physicians according to usual clinical practice. The study will not assign any treatment, randomization, or experimental intervention.

Study summary

This is an observational cohort study conducted at Ningbo No. 2 Hospital. The study will include patients with knee-related sports injuries or degenerative knee conditions who receive routine clinical care. The purpose is to build a standardized real-world clinical cohort and evaluate knee injury, degeneration, recovery, and long-term outcomes.

After informed consent, participants will undergo baseline data collection, including medical history, laboratory tests, questionnaires, X-ray and MRI imaging, and functional assessments. Patients younger than 50 years will mainly be assessed for sports injury and functional recovery, while patients aged 50 years or older will receive additional sarcopenia-related assessments such as grip strength, DXA testing, and gait evaluation.

No experimental treatment, randomization, or intervention will be assigned. Participants will be followed at about 6, 12, and 24 months after treatment or surgery to assess knee function, imaging changes, reinjury, reoperation, pain, quality of life, falls, and functional decline. The study plans to enroll about 500 participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Patients who plan to receive relevant clinical evaluation or treatment at Ningbo No. 2 Hospital and are able to complete baseline assessment. * Patients with a clinical diagnosis of knee-related injury or degenerative knee disease. * Patients who are willing to provide informed consent and participate in follow-up. Exclusion Criteria: * Patients who are unable to complete the core baseline assessments or have substantial missing key clinical information. * Patients with severe comorbid conditions or cognitive impairment that may affect assessment of the main outcomes or prevent participation in follow-up. * Patients who are considered by the investigator to be unsuitable for inclusion in this cohort.

Primary outcome measure(s)

  • Change in Knee Function Scores(IKDC) — Baseline, 6 months, 12 months, and 24 months after treatment or surgery
    Change in knee function from baseline will be assessed using validated patient-reported outcome scores(IKDC)
  • Change in Imaging-Based Knee Degeneration(T1/T2 mapping) — Baseline, 6 months, 12 months, and 24 months after treatment or surgery
    Progression of knee degeneration will be assessed using quantitative MRI sequences ( T1/T2 mapping).

Trial sites (1)

FacilityCityRegionStatus
Ningbo NO.2 Hospital,Wenzhou Medical University Ningbo Zhejiang Recruiting

More Ningbo No.2 Hospital trials in China

LLL vs. SDL for LBBP: A Non-inferiority RCT Starting soon
Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection Starting soon

Other trials for the same condition

The Effects of Knee Brace and Muscle Training on Osteoarthritis Patients Enrolling by invitation
Comparison of Postoperative Functional Outcomes Between Subvastus and Medial Parapatellar Approach in Total Knee Arthroplasty Starting soon
Clinical Study of Acupuncture Treatment of Knee Osteoarthritis Recruiting
ASKC200 for Knee Osteoarthritis Pain Active, not recruiting
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07592871 on ClinicalTrials.gov ↗ ← All trials in China